How does Creative Biolabs specifically achieve "superagonism" to enhance effector cell activity in oncology?

We go beyond simply silencing CD25 by introducing proprietary mutations that enhance the molecule's affinity for the signaling component, CD122/CD132. This structural change maximizes the STAT5 phosphorylation signal specifically in CD8+ T cells and NK cells, resulting in a more potent anti-tumor response at lower systemic concentrations.

What methods do you use to mitigate the risk of anti-drug antibodies developing against the long-acting construct?

Our primary strategy is to use homologous components (such as the human Fc domain) and stable, irreversible covalent linkages (like those found in grafted antibodies or optimized fusions), which are less prone to generating the neo-epitopes responsible for triggering ADA responses compared to non-covalent complexes or highly divergent muteins.

IL-2 Long-Acting Therapeutics Development Service

Creative Biolabs' IL-2 long-acting therapeutics development service provides a customized, end-to-end platform for engineering next-generation IL-2 molecules. We provide scientifically rigorous development resulting in pre-clinically validated candidates with optimized receptor bias and extended half-life via stable, covalent fusion constructs. Clients gain a patent-defensible lead sequence, comprehensive PK/PD data demonstrating reduced toxicity and enhanced efficacy, and a clear, expedited path to advanced research.

Introduction of IL-2 Long-Acting Therapeutics Development Service

IL-2 is a cornerstone cytokine, but its use has been hampered by its short half-life and dual function: promoting immunity via the intermediate-affinity CD122/CD132 receptor and regulating tolerance via the high-affinity CD25/CD122/CD132 receptor, which is highly expressed on Treg cells. Next-generation therapeutics must engineer selective signaling (e.g., CD25 silencing or CD122 superagonism) and extend circulation time to minimize toxicities, reduce off-target Treg expansion, and enable effective cancer and autoimmunity therapies.

What We Can Offer

Customizable Half-Life Extension Formats

We specialize in multiple long-acting scaffolds, including optimized Fc-fusion, albumin-binding domains, and site-specific Glyco-PEGylation, allowing clients to choose the ideal PK profile for reduced renal clearance.

Covalently Stabilized Constructs

Our proprietary single-molecule design methodology ensures the IL-2 component is irreversibly linked to its scaffold, preventing in vivo dissociation and guaranteeing sustained, selective signaling throughout the dosing interval.

End-to-End Immunogenicity Risk Mitigation

We utilize advanced in silico modeling and homology assessment to strategically design constructs with minimal neo-epitopes, safeguarding against anti-drug antibody (ADA) generation and protecting your therapeutic pipeline.

Data-Driven Lead Optimization

You receive a complete data package - including quantitative SPR binding kinetics, cell-based STAT5 phosphorylation assays, and in vivo PK/PD modeling - all focused on maximizing your therapeutic index and accelerating transition to the advanced research phase.

IL-2 Long-Acting Therapeutics Development Service at Creative Biolabs

Highlights

Advanced Engineering Focus

Creative Biolabs leads cytokine engineering by actively mitigating pitfalls inherent in earlier IL-2 programs, focusing on the core challenges of toxicity and short half-life that have consistently hindered development success.

Dual Core Expertise

Our primary differentiation lies in dual expertise: achieving potent CD122 Superagonism for enhanced effector signaling and robust immunogenicity risk mitigation to safeguard the long-term viability of therapeutic candidates.

Stable Construct Specialization

Unlike historical, non-site-specific PEGylation, we specialize in covalently stabilized constructs, such as engineered Fc fusions, that permanently shield the CD25 binding site, ensuring consistent and highly selective signaling profiles.

Predictable Pharmacokinetics

These specialized covalently stabilized constructs deliver consistent, selective signaling and predictable pharmacokinetics. This technical advantage, supported by proprietary published data, confirms our high success rates in generating superior IL-2 molecules.

To initiate engagement with Creative Biolabs, we invite you to get a quote today.

Customer Reviews

FAQs

Related Services

In Vivo Efficacy

Comprehensive animal model testing is utilized to validate anti-tumor or immunosuppressive activity and assess critical safety endpoints like vascular leak syndrome.

Learn More →

Antibody Engineering

Services for generating high-affinity antibodies required for Fc-fusion or novel grafted antibody constructs, ensuring optimal construct stability and target specificity.